Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 7/20 | 0.69 |
| ▸ | MTNR1B | P49286 | 6/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.60 |
| ▸ | NPC1 | O15118 | 3/20 | 0.58 |
| ▸ | RAB9A | P51151 | 3/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.58 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.58 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.58 |
| ▸ | RELA | Q04206 | 1/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | NQO2 | P16083 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3401444 | 0.82 | MTNR1A (0.77) | MTNR1AMTNR1BALDH1A1NPC1RAB9A | |
| SCHEMBL3400130 | 0.82 | MTNR1A (1.00) | MTNR1AMTNR1BALDH1A1NPC1RAB9A | |
| SCHEMBL27823812 | 0.81 | MTNR1A (0.71) | MTNR1AMTNR1BALDH1A1NPC1RAB9A | |
| SCHEMBL4463389 | 0.80 | SMN1; SMN2 (0.57) | MTNR1AMTNR1BALDH1A1SMN1; SMN2KMT2A | |
| SCHEMBL140038 | 0.78 | SMN1; SMN2 (0.67) | MTNR1AMTNR1BALDH1A1SMN1; SMN2KMT2A | |
| SCHEMBL3397574 | 0.77 | MTNR1A (0.69) | MTNR1AMTNR1BALDH1A1NPC1RAB9A | |
| SCHEMBL5072982 | 0.75 | POLB (0.58) | MTNR1AMTNR1BSMN1; SMN2POLB | |
| SCHEMBL15614663 | 0.75 | MTNR1A (0.48) | MTNR1AMTNR1BALDH1A1NQO2 | |
| SCHEMBL2891083 | 0.74 | FPR2 (0.60) | NPC1RAB9ASMN1; SMN2KMT2A | |
| SCHEMBL9632174 | 0.74 | POLB (0.57) | ALDH1A1SMN1; SMN2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9573914-B2 | Process for preparing benzothiazepines from gamma-aminoalkylbenzenes | LES LABORATOIRES SERVIER (FR) | 2017-02-21 | — | — | US | disclosed |
| US-9573914-B2 | Process for preparing benzothiazepines from gamma-aminoalkylbenzenes | LES LABORATOIRES SERVIER (FR) | 2017-02-21 | — | — | US | disclosed |
| US-20140121368-A1 | PROCESS FOR PREPARING BENZOTHIAZEPINES FROM GAMMA-AMINOALKYLBENZENES | ARMGO PHARMA, INC. (US) | 2014-05-01 | — | — | US | disclosed |
| US-20140121368-A1 | PROCESS FOR PREPARING BENZOTHIAZEPINES FROM GAMMA-AMINOALKYLBENZENES | ARMGO PHARMA, INC. (US) | 2014-05-01 | — | — | US | disclosed |
| US-8618282-B2 | Process for preparing benzothiazepines from gamma-aminoalkylbenzenes | LES LABORATOIRES SERVIER (FR) | 2013-12-31 | — | — | US | disclosed |
| EP-2250159-B1 | PROCESS FOR PREPARING BENZOTHIAZEPINES FROM GAMMA-AMINOALKYLBENZENES | ARMGO PHARMA INC (US) | 2011-12-07 | — | — | EP | disclosed |
| EP-2250159-B1 | PROCESS FOR PREPARING BENZOTHIAZEPINES FROM GAMMA-AMINOALKYLBENZENES | ARMGO PHARMA INC (US) | 2011-12-07 | — | — | EP | disclosed |
| EP-2250159-A1 | PROCESS FOR PREPARING BENZOTHIAZEPINES FROM GAMMA-AMINOALKYLBENZENES | Armgo Pharma, Inc. (US) | 2010-11-17 | — | — | EP | disclosed |
| WO-2009111463-A1 | PROCESS FOR PREPARING BENZOTHIAZEPINES FROM GAMMA-AMINOALKYLBENZENES | ARMGO PHARMA, INC. (US) | 2009-09-11 | — | — | WO | disclosed |
| WO-2009111463-A1 | PROCESS FOR PREPARING BENZOTHIAZEPINES FROM GAMMA-AMINOALKYLBENZENES | ARMGO PHARMA, INC. (US) | 2009-09-11 | — | — | WO | disclosed |
| US-20090227788-A1 | PROCESS FOR PREPARING BENZOTHIAZEPINES FROM GAMMA-AMINOALKYLBENZENES | RYCARMA THERAPEUTICS, INC. | 2009-09-10 | — | — | US | disclosed |
| US-20090227788-A1 | PROCESS FOR PREPARING BENZOTHIAZEPINES FROM GAMMA-AMINOALKYLBENZENES | RYCARMA THERAPEUTICS, INC. | 2009-09-10 | — | — | US | disclosed |
| US-20090227788-A1 | PROCESS FOR PREPARING BENZOTHIAZEPINES FROM GAMMA-AMINOALKYLBENZENES | RYCARMA THERAPEUTICS, INC. | 2009-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140121368-A1 | PROCESS FOR PREPARING BENZOTHIAZEPINES FROM GAMMA-AMINOALKYLBENZENES | TPMT, SULT2A1, GABRA4 | MTNR1A 1676/4885MTNR1B 1156/4885ALDH1A1 55/4885 |
| US-20090227788-A1 | PROCESS FOR PREPARING BENZOTHIAZEPINES FROM GAMMA-AMINOALKYLBENZENES | TPMT, SULT2A1, KCNJ2 | MTNR1A 1674/4885MTNR1B 1154/4885ALDH1A1 57/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.